BioNTech is purchasing a new manufacturing facility in Marburg, Germany from Novartis.
The companies did not disclose the value of the deal, but BioNTech said that it is planning to use the site to ramp up production of the coronavirus vaccine it is developing with Pfizer. The companies were previously aiming to produce up to 100 million doses of their vaccine by the end of this year and another 1.3 billion shots in 2021. With the new facility, BioNTech said that those production estimates can be increased by several hundred million doses.
BioNTech hopes that its vaccine candidate will achieve an “immunization effect” of 70-75 percent and be submitted for regulatory review by early November.
The 300 employees at the Novartis site will now join BioNTech.
Read the full Reuters report.
